ADC Pharma (ADCT) - שיעור רווח גולמי

סמלים רשמיים של חברת ADC Therapeutics Corp (ADCT)

ADC Therapeutics is investing massive resources into developing advanced ADC conjugates to combat hematologic cancer. The gross profit margin on the GURU.Markets service generates this chart, where the current metric equals 88.40. This trend reflects the expansion of Zynlonta and interest from pharma behemoths in the platform, although management is currently optimizing commercial expenses to curb cash burn amid fierce competition.

adctherapeutics.com (ADCT) - שולי רווח גולמי מ-04.07.2022 עד 20.11.2026

פילוחים אנליטיים ודוחות נתונים של חברת ADC Therapeutics (ADCT)

- מחיר ותחזית קונצנזוס למחירים:
הערכת שווי פונדמנטלית:ADC Therapeutics
מוצר ממותג של ADC Pharma

Institutional capital evaluates ADC Therapeutics (ADCT) through the lens of its lymphoma drug's monetization efficiency, where margin stability determines the investment horizon. Analyzing this gross margin chart, an investor sees the revenue share net of direct production costs, which is critically important for assessing the viability of the business model and the reliability of the asset given high R&D expenses and low cash flow predictability.